The neuropathology of chronic traumatic encephalopathy: a review and comparison with other neurodegenerative disorders by Turner, Dylan
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
The neuropathology of chronic
traumatic encephalopathy: a
review and comparison with other
neurodegenerative disorders
https://hdl.handle.net/2144/19468
Boston University
	 	 	
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
THE NEUROPATHOLOGY OF CHRONIC TRAUMATIC 
ENCEPHALOPATHY: A REVIEW AND COMPARISON WITH OTHER 
NEURODEGENERATIVE DISORDERS 
 
 
 
 
by 
 
 
 
 
DYLAN TURNER 
 
B.S., Boston College, 2015 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2016  
	 	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 by 
 DYLAN TURNER 
 All rights reserved  
	 	 	
Approved by 
 
 
 
 
First Reader   
 Dr. Elizabeth R. Whitney, Ph.D. 
 Assistant Professor of Anatomy and Neurobiology 
 
 
Second Reader   
 Maryann MacNeil, M.A. 
 Instructor of Anatomy and Neurobiology 
 
 
		 iv 
THE NEUROPATHOLOGY OF CHRONIC TRAUMATIC 
ENCEPHALOPATHY: A REVIEW AND COMPARISON WITH OTHER 
NEURODEGENERATIVE DISORDERS 
DYLAN TURNER 
ABSTRACT  
In the past decade, numerous studies have examined the correlation between 
repetitive head trauma in athletes who participated in contact sports and the development 
of various personality, behavioral, and cognitive changes. Autopsy data from these 
athletes have uncovered unique patterns of neuropathology that are believed to be 
associated with the observed clinical symptoms, and together characterize a condition 
known as chronic traumatic encephalopathy (CTE). Historically, the condition was 
known as “dementia pugilistica” commonly found in boxers; however, recent studies 
have identified cases of CTE in retired football players, hockey players, soccer players, 
war veterans, and other non-athletes. CTE is a progressive disease and clinical signs often 
appear many years after the trauma. These symptoms frequently include depression, 
aggression, suicidality, short-term memory loss, and executive functioning impairments. 
Postmortem examinations of individuals with CTE reveal distinct gross and microscopic 
pathology, including atrophy of the frontal and temporal cortices, sulcal accumulation of 
hyperphosphorylated tau, β-amyloid deposition, and TAR DNA-binding protein 43 
abnormalities. Although current hypotheses suggest that repetitive head trauma causes 
the development of CTE, the lack of prospective studies hinders our ability to definitively 
determine its etiology. Likewise, the inability to diagnose CTE in vivo has constrained 
		 v 
our attempts to systematically examine the disease’s progressive nature. The goal of this 
paper is to review the past and current literature on CTE in boxers and football players. 
We also discuss current hypotheses concerning CTE’s clinical presentation and 
neuropathology, and situate CTE within the context of other neurodegenerative diseases. 
Finally, we address the current limitations of CTE research and propose key objectives 
for future studies.   
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INTRODUCTION 
Chronic traumatic encephalopathy (CTE) is an irreversible and progressive 
neurodegenerative syndrome that manifests as an array of motor, behavioral, and 
cognitive deficits (McKee et al., 2013). CTE is a member of a family of known 
tauopathies, including Alzheimer’s disease (AD), and displays distinct gross and 
microscopic pathology (McKee et al., 2013). Specifically, the disease is characterized by 
the accumulation of hyperphosphorylated tau throughout the neocortex, primarily in the 
form of neurofibrillary tangles (NFTs) and neuritic threads (NTs) (McKee et al., 2013). 
CTE has been associated with multiple mild traumatic brain injuries (mTBIs), also 
known as concussions, and clinical symptoms commonly appear many years after initial 
injury (McKee et al., 2013). 
Over the past decade, the scientific community has expressed an increased interest 
in better understanding the epidemiology of CTE. The rise in CTE research has been 
linked to an increase in the mortality rate in professional athletes, specifically former 
NFL players, who display mood and behavioral changes consistent with the disease. The 
growing number of CTE-related deaths in retired football players has garnered significant 
media attention, which in combination with increasing scientific evidence, has led many 
to assume a causal relationship between clinical symptoms and pathological findings. 
While this hypothesis may be true, a majority of our knowledge of CTE has been 
obtained retrospectively through case reports and case series. This retrospective approach 
creates the potential for selection bias, and limits the amount of information available 
about the disease. The lack of prospective studies on CTE has led to ambiguity 
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surrounding its etiology as well as its connection to other neurodegenerative disorders, 
such as AD.  
Specific Goals 
The purpose of this paper is to achieve the following four goals. First, this review 
will provide a historical overview of the literature, spanning from the emergence of 
punch drunk syndrome in the late 1920s to the recently discovered cases of CTE in 
former NFL players. The second goal is to provide a discussion of current hypotheses 
regarding the clinical symptoms and neuropathology associated with CTE and their 
connection to mTBI. Specifically, this paper will take a closer look at several sentinel 
studies through which most of our knowledge of the disease has been obtained. Third, 
this report will review our current understanding of the relationship between CTE and 
other neurodegenerative diseases, particularly AD. Greater knowledge of the connections 
between the clinical presentation and pathological findings of CTE with those of other 
conditions may reveal similarities in pathogenesis. Finally, this paper will discuss the 
current limitations on CTE research posed by the inability to diagnose the disease in vivo 
and the subsequent lack of prospective studies on its epidemiology. 	  
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HISTORICAL CONTEXT 
CTE and Boxing 
Before the early 1900s, little attention was given to the role of brain trauma in the 
development of neurodegenerative disease. In 1927, Osnato et al. published one of the 
first formal investigations of the relationship between repetitive concussions and 
structural damage to the brain parenchyma. Osnato et al. (1927) assessed the clinical 
symptoms of 100 concussed individuals as well as the microscopic pathology present in 
the brain of a 33-year-old male who died of internal injuries suffered in a motorcycle 
accident. Although the subject experienced acute brain trauma, no signs of fracture or 
laceration were present upon postmortem analysis (Osnato et al, 1927). In contrast, 
microscopic examination of the individual’s brain revealed small petechial hemorrhages 
throughout the centrum ovale and corpus callosum (Osnato et al., 1927). Perivascular and 
peri-glial degeneration of the brain tissue were also visible, and similar to that seen in 
epidemic encephalitis (Osnato et al., 1927). The findings of Osnato et al. (1927) were 
significant for two reasons. First, at the time of this study it was commonly believed that 
concussion was “an essentially transient state which does not comprise any evidence of 
structural cerebral injury,” (Osnato, 1927). The results of their study disproved this 
hypothesis. Second, their clinical and pathological evidence suggested that a single mTBI 
could have chronic neurodegenerative consequences. The findings of Osnato et al. (1927) 
spurred additional investigations on the effects of brain trauma, a majority of which 
focused on deficits displayed by professional boxers. 
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In 1928, Harrison Martland, a pathologist from New Jersey, introduced the term 
“punch drunk syndrome” to characterize the immediate psychological and physical 
impairments experienced by boxers following several blows to the head (Martland, 
1928). He examined 23 cases of “punch drunk syndrome” in retired fighters; however, 
Martland personally examined only 5 of these fighters and received information on the 
other 18 boxers from a boxing promoter (Gardner, 2013)  Generally, he describes punch 
drunk individuals s as “cuckoo,” “goofy,” and “slug nutty,” and specifically notes that 
these findings were more common amongst “slugging” boxers (Martland, 1928). 
According to Martland, “sluggers” were poor fighters, who sustained numerous blows to 
the head before delivering a single knockout punch to win their matches (Martland, 
1928). Frequently, these fighters required several hours to regain normal cognitive 
function following a fight, and on rare occasions lost consciousness for extended periods 
of time (Martland, 1928).  Martland notes a correlation between the number of bouts 
fought and the severity of motor symptoms shown by fighters following retirement 
(Martland, 1928). 
Of the five individuals he personally examined, Martland provides a detailed 
analysis of the symptoms of only a single fighter (Gardner, 2013). This individual began 
fighting at age 16, but retired from the sport at age 23 after developing symptoms of 
punch drunk syndrome (Martland, 1928). Although he displayed numerous motor 
deficits, such as tremor in his left hand and abnormal gate, this fighter surprisingly lacked 
signs of intellectual impairment (Martland, 1928). These findings were significant 
because they reinforced previous hypotheses that multiple mTBIs may be associated with 
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distinct neurodegenerative changes (Martland, 1928). Specifically, Martland identified a 
common pattern of motor deficits found in fighters both during and after their careers in 
boxing that he believed was caused by repetitive blows to the head (Martland, 1928). 
Numerous studies on punch drunk syndrome followed as well as several new names for 
the condition to convey its progressive nature; these included “traumatic encephalopathy” 
introduced by Parker in 1934 and “dementia pugilistica” (DP) by Millspaugh in 1937 
(Millspaugh, 1937; Parker, 1934). 
In 1940, KM Bowman presented one of the first cases involving a professional 
boxer who developed not only motor impairments characteristic of DP, but also cognitive 
and behavioral changes that worsened over time. During his career, this fighter suffered 
numerous knockouts and later, became so mentally ill that he was barred from the sport 
(Bowman, 1940). The authors described his personality as erratic, paranoid, depressed, 
violent, and even childish at times (Bowman, 1940). His cognitive deficits included 
memory loss, disorientation, and unawareness of his abnormal behavior (Bowman, 1940). 
Unlike punch drunk syndrome, these psychological changes persisted through out his 
lifetime and, in fact, worsened with advancing age (Bowman, 1940). These findings led 
Bowman to introduce the term “chronic traumatic encephalopathy” to describe both the 
chronic and progressive nature of the boxer’s condition (Bowman, 1940). 
Much of our knowledge of the pathology associated with CTE in boxers was 
discovered by Corsellis et al., who presented the first case series on the disease in 1973. 
This study presented the autopsy results of 15 former fighters, revealing numerous signs 
of gross pathology, including marked cerebral atrophy, enlargement of the lateral and 
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third ventricles, and pallor of the substantia nigra (Meehan et al., 2015).  Microscopic 
analysis unveiled significant deposits of NFTs in the frontal and temporal cortex without 
the presence of β-amyloid (Aβ) plaques, which are characteristic of AD (Corsellis et al., 
1973; Meehan et al., 2015).  In 1990, however, these same cases were re-investigated by 
Roberts et al. using immunocytochemical assays, and widespread Aβ plaques were 
discovered in each of the brains found to have NFTs by Corsellis et al in 1973 
(Montenigro, Corp, Stein, Cantu, & Stern, 2015). Although Corsellis et al. (1973) 
contributed greatly to our knowledge of CTE pathology, one of the most valuable results 
of this study was its suggestion that CTE and AD may develop through similar 
mechanisms.  
Over the past five years, there has been debate amongst researchers over the 
possibility that the form of CTE studied historically in boxers may be clinically and 
pathologically distinct from that found recently in professional football players. In 2013, 
Gardner et al. (2013) and McCrory et al. (2013) argued that the work of Bowman et al. 
(1940), Roberts et al. (1969), and Corsellis et al. (1973) characterize a “classical” form of 
CTE experienced by boxers; whereas, more recent studies on CTE in football players 
present a unique “modern” form of CTE. Gardner et al. (2013) suggests that the key 
distinction between the two definitions of CTE lies in the type of clinical symptoms 
predominately displayed by effected individuals. Although motor, cognitive, and 
psychological deficits may each be present in both types of CTE, the classical form is 
characterized by primarily motor deficits and is associated with former boxers; whereas, 
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the modern form displays mostly cognitive and behavioral abnormalities and is found in 
football players (Gardner, 2013; McCrory, 2013).  
Although there is evidence that both supports and opposes the classical vs. 
modern CTE model, a majority of the scientific community resists this hypothesis. In a 
2015 review, Montenigro et al. (2015) argues that Gardner et al. (2013) and McCrory et 
al. (2013) overlooked statements by the authors of these historical reports that specify 
their intention to focus on boxers’ motor impairments “leaving aside for later 
consideration the question of dementia and psychiatric disturbance, which undoubtedly 
occur in some cases” (Montenigro et al., 2015; Roberts, 1969). Likewise, Corsellis et al. 
(1973) states that the cognitive and behavioral deficits of retired fighters “have rarely 
been looked” at (Corsellis et al., 1973; Montenigro et al., 2015). Furthermore, Johnson 
(1969) proposed a classification system for boxer’s psychological abnormalities that 
consists of “four organic psychosyndromes,” specifically a “chronic amnesic state, 
dementia, rage reactions in personality disorder, and the morbid jealousy syndrome” 
(Johnson, 1969; Mez, Stern, & McKee, 2013). While the idea of a distinction between the 
classical and modern forms of CTE as unique diseases remains controversial, a closer 
look at the historical context of CTE in football players may shed light on how the 
disease effects athletes of both sports.   
CTE and Football 
Although much of today’s knowledge of modern CTE has been discovered in the 
last several decades, reports of the potential neurodegenerative effects of brain trauma in 
American football players were recorded as early as the late 1800s (Montenigro et al., 
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2015). In their 2015 study, Montenigro et al. describes the origin of the first football 
helmet, worn by a Navy Midshipman, named Joseph M. Reeves. The player had the 
leather helmet made after being warned by a physician that he could develop “traumatic 
insanity” if he continued to suffer concussions while playing football (Montenigro et al., 
2015). Additionally, Osnato et al. (1927) references the clinical symptoms experienced 
by football players as well as athletes of other sports after being “knocked out” during 
games. Furthermore, both Bowman et al. (1940) and Martland et al. (1943) mention the 
possibility of multiple concussions causing neurological impairments in football players 
that are similar to those experienced by boxers. (Montenigro et al., 2015). 
Specific reports of symptomatic football players were first published in the 1930s. 
In 1933, the Homeopathic Medical Society of the State of Pennsylvania released a case 
study of a football player who displayed signs of “psychopathic personality,” which 
resembled the symptoms often found in boxers (Montenigro et al., 2015; “Punch-drunk 
boxers and football players.,” 1933). Additionally, in 1936, the New York Journal of 
Medicine published a study that compared the “punch drunk state” displayed by athletes 
of both sports (Montenigro et al., 2015; “Psychoneurosis,” 1933). Furthermore, in 1937, 
Frank Scully, a former Columbia University football player, stated that seven of his 
former teammates suffered from cognitive and motor impairments following their 
retirements from football (Montenigro et al., 2015). He argued that football players may 
be at greater risk of developing neurodegenerative symptoms compared with boxers 
because of the greater frequency of traumatic blows to the head in football compared to 
boxing (Montenigro et al., 2015). As noted by Montenigro et al. 2015, each of these 
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examples demonstrate that members of the scientific community were well aware of the 
potential deleterious effects associated with American football long before the recent 
surge of studies on CTE. 
Since the early 2000s, CTE research has gained significant attention from both the 
media and scientific community due to the increased awareness of the incidence of the 
disease amongst NFL players. This rise in CTE research began in 2005 after Omalu et al. 
published their landmark study that provided the first official postmortem diagnosis of 
CTE in a former football player. Before his death in 2002, Mike Webster displayed a 
plethora of cognitive and behavioral abnormalities, including aggression, mood disorders, 
suicidality, and Parkinsonism (Meehan et al., 2015; Omalu et al., 2005). Although gross 
examination revealed a normal brain, microscopic investigations unveiled numerous 
signs of pathology similar to those found in past studies on professional boxers. Omalu et 
al. (2005) noted NFTs within the depths of the sulci of the neocortex, widespread Aβ 
plaques, and tau-positive neuritic threads (Meehan et al., 2015; Omalu et al., 2005). The 
findings of Omalu et al. (2005) were immensely significant as they solidified hypotheses 
on the potential risks associated with brain trauma experienced in sports beyond boxing. 
Following the 2005 report, additional studies were published by Omalu et al. in 2006, 
2010, and 2011, as well as numerous reports by other research groups. Collectively, this 
rise in CTE research has revealed cases of suspected CTE in wrestlers, victims of abuse, 
blast-exposed military veterans, and athletes in other contact sports (McKee et al., 2009, 
2013; Omalu et al. 2006, 2011). 
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In 2009 and 2013, McKee et al. published two of the largest and most influential 
case series to date. The 2009 report examined 51 cases of suspected CTE, including 1 
football player, 2 boxers, and 3 other professional athletes, revealing clinical and 
pathological findings similar to those seen by Omalu et al. (2005). Their 2013 study is 
currently the largest case series to date and consists of 85 cases of CTE in both athletes 
and non-athletes. Of these 85 individuals, 64 were former professional athletes, including 
33 former NFL players, and 21 individuals were military veterans (Gardner, 2013; 
McKee et al., 2013). The great sizes of both case series presented by McKee et al. 
allowed their results to substantially reinforce previous hypotheses of a causal link 
between mTBI and CTE, and provide valuable insight into the relationship between CTE 
and other neurodegenerative diseases. Since the work of Omalu et al. and McKee et al. 
has been so influential in expanding our knowledge of CTE, a closer look at the 
significant contributions of each of their landmark studies will provided in later sections 
of this paper.  
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CLINICAL PRESENTATION 
CTE presents clinically as a plethora of motor, behavioral, and cognitive 
abnormalities that typically arise between the ages of 35 and 60 (Table 1). Today, it is 
believed that there are two common clinical presentations associated with CTE. This 
“subtype” hypothesis was presented by Stern et al. in 2013 in a study that assessed the 
clinical symptoms of a variety of patients with backgrounds in different contact sports 
(Stern et al., 2013; Montenigro et al. 2015). The first subtype displays predominately 
mood and behavioral abnormalities with a younger age of onset; whereas, patients with 
the second subtype show mainly cognitive deficits that appear at older ages (Stern et al., 
2013; Montenigro et al. 2015). According to Stern et al. (2013), individuals with changes 
in mood and behavior experienced symptoms at an average age of 34.5 years and those 
with cognitive impairments displayed symptoms at a mean age of 58.5 years. In 2014, 
Montenigro et al. performed a study that both verified the findings of Stern et al. (2013), 
but also added a third subtype of common clinical presentations (Stern et al., 2013; 
Montenigro et al. 2014, 2015). Individuals with this third subtype display symptoms that  
are a combination of those of the other two subtypes; patients may present with signs of 
mood, behavior, and cognitive defecits that appear at both young and old ages (Stern et 
al., 2013; Montenigro et al. 2014, 2015).  
Although most members of the scientific community resist previous hypotheses 
that boxers and football players experience distinct diseases, numerous differences in the 
clinical presentations of CTE in athletes of these sports have been recorded. In 2009, 
McKee et al. discovered a significant difference in the duration of symptomatic illness 
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between football players and boxers. This statistic ranged from 3 to 10 years in football 
players with a mean of 6 years and a range of 5 to 46 years in boxers with a mean of 20.6 
years (McKee et al., 2009). Additionally, McKee et al. found that behavioral and mood 
changes displayed by former football players were extreme and often resulted in 
traumatic deaths; whereas, the disease course in boxers was “smoldering, yet 
symptomatic” (McKee et al., 2009). These findings were significant because they not 
only provided evidence in support of the “subtype” hypothesis later made by Stern et al. 
in 2013, but also suggested that the subtypes experienced by boxers and football players 
may be different. The results of McKee et al. (2009) support the belief that football 
players experience predominately the behavioral and mood subtype that appears at 
younger ages and results in earlier deaths; while, boxers commonly display the cognitive 
subtype that becomes apparent at older ages and results in later deaths.  
Furthermore, in 2013, Gardner et al. and McCrory et al. argued that boxers with 
the cognitive subtype of CTE typically display greater motor deficits than football players 
with the behavioral and mood subtype of the disease. In boxers, motor symptoms 
typically appear 10-20 years after retirement when most fighters are 50 to 60 years old, 
and the severity of these symptoms is believed to increase with career length and total 
number of matches fought (Gardner, 2013). Gardner et al. (2013) and McCrory et al. 
(2013) also suggest that boxers’ physical and motor impairments may even be more 
severe than their cognitive symptoms. These hypotheses made by Gardner et al. and 
McCrory et al. parallel a scheme proposed by Roberts et al. in 1990 for the development 
of cognitive and motor deficits in former fighters. Roberts et al. (1990) states that boxers 
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first display “affective disturbances and psychotic symptoms.” Second, fighters 
experience marked Parkinsonian motor deficits, memory loss, dysarthria, movement 
difficulties (Roberts et al., 1990). Finally, in the third stage of disease development, 
effected individuals show worsened motor deficits, signs of dementia, cognitive 
disability, and pyramidal tract disease (Roberts et al., 1990).  
 Although the two subtype hypothesis has not been universally accepted within the 
scientific community, recent research has demonstrated that the behavioral and mood 
changes (Table 1) experienced by football players are commonly more severe than their 
cognitive and motor impairments (Gardner, 2013). Behavioral abnormalities typically 
arise first after a long latent period between injury and onset of symptoms (Omalu et al., 
2005). These symptoms may include paranoid thoughts, problems with social 
interactions, exaggerated responses to stress, highly inconsistent mood, severe 
depression, insomnia, suicidality, and disinhibition (Omalu et al., 2011). Cognitive 
deficits appear later and consist of dementia, disorientation, lack of attention, speech 
impairment, information processing and executive functioning that is commonly apparent 
in work performance, management of finances, and deterioration of socioeconomic status 
(Omalu et al., 2011; Gardner, 2013; Jordan, 2013). Cases of CTE in football players have 
also exhibited a variety of highly abnormal behavioral changes, including increasing 
religiosity, sexual indiscretions, indulgence in illegal acts, and intentional disruption of 
intimate and familial relationships (Omalu et al., 2011). A key distinction between the 
clinical presentation of CTE in football players and boxers lies in the tendency of clinical 
symptoms to progress with age. Football players commonly display mood and behavioral 
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that worsen over time; whereas, boxers are less likely to show progressive losses in 
cognitive function (Gardner, 2013). Motor deficits, such as ataxia, dysarthria, 
Parkinsonian tremor spasticity, and coordination dysfunction, are commonly present in 
affected football players; however, as previously noted, these impairments are typically 
less severe than neuropsychiatric abnormalities (Jordan, 2013).  
Overall, it is currently believed that the clinical presentation of CTE may be 
broken down into two subtypes. The first subtype is characterized by predominately 
cognitive defecits and is more common amongst former boxers than retired football 
players. Fighters with this subtype frequently present with motor defecits that in some 
cases may be more severe than cognitive impairments. Generally, cognitive symptoms of 
effected boxers do not progress with age. The second subtype is dominated by mood and 
behavior abnormalities, and is more common amongst former football players than 
retired boxers. Football players with the second subtype typically display less severe 
motor impairments; however, in most cases, mood and behavioral changes drastically 
worsen with age. Because of this difference in symptom progression, football players 
with CTE commonly die earlier than boxers suffering from the disease.  
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Table 1. Cognitive, behavioral and mood abnormalities consistent with CTE. Table 
taken from Omalu et al., 2011.   
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CONCUSSION AND mTBI 
Definition of Concussion 
Before discussing the neuropathology associated with CTE, it is important to 
understand the definition of concussion and mechanism of injury associated with mTBI. 
Historically, the terms “concussion” and “mTBI” have been used interchangeably in 
discussions on CTE. According to the American Academy of Neurology, concussion and 
mTBI describe any biomechanically induced alteration of brain function that commonly 
results in loss of consciousness and short-term impairments in memory, orientation, and 
cognitive function (Giza et al., 2013; Mez et al., 2013). All reported cases of CTE have 
been associated with a history of repetitive brain trauma; however, not all cases have 
been linked to concussions; thus, it is currently believed that sub-concussive blows may 
play a role in CTE pathogenesis (Mez et al., 2013). CTE is considered distinct from both 
the immediate symptoms of concussive impacts as well as other conditions that 
commonly result from concussions, such as post concussive syndrome and second impact 
syndrome, since its clinical symptoms typically appear many years after suffering 
multiple mTBIs (Mez et al., 2013).  
mTBI  Mechanism of Injury 
 When an individual suffers brain trauma,	cerebral injury occurs as a result of 
rapid acceleration and deceleration forces on by the brain during impact (McKee et al., 
2009; Jordan, 2013). Specifically, rotational acceleration, linear acceleration, and impact 
deceleration may result in neuronal injury (Jordan, 2013). Rotational acceleration causes 
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axons to stretch and tear, resulting in concussion-like symptoms (Jordan, 2013). Linear 
acceleration may cause contusions of the cerebral cortex and brainstem (Jordan, 2013). 
Finally, impact deceleration can lead to neuronal injury in the cerebral cortex on both the 
side of the head that suffered the impact (coup injury) and the opposite side of the head 
(contrecoup injury) (Jordan, 2013). 
Another frequent consequence of concussive impacts is the creation of a “fluid 
wave” in the lateral ventricles that imposes shearing forces on the septum pellucidum 
(McKee et al., 2009). These forces likely cause cavum septum pellucidum, septal 
fenestrations, and other septal defects (McKee et al., 2009). Since the “fluid wave” 
occurs primarily in the lateral ventricles, impacts that take place in the coronal plane (side 
to side) are believed to cause more severe injuries than blows that occur in the sagittal 
plane (McKee et al., 2009).   
mTBI  Neuropathology 	 The most significant deleterious effects of acute mTBI are neuronal injury and 
death, formation and deposition of abnormal proteins, and breakdown of the blood brain 
barrier.	Neuronal loss associated with mTBI is believed to be caused by multiple factors, 
including direct physical damage, increased GABA release and associated tissue necrosis, 
activation of apoptotic cascades, focal ischemia, and abnormal protein deposition 
(McKee et al., 2009). In mouse models, it has been demonstrated that an impact to the 
side of the head can lead to immediate, irreversible, and progressive neuronal loss as well 
as degeneration of the cortex, diencephalon, and hippocampus within one year (McKee et 
al., 2009). The adverse effects of chronic and progressive neuronal loss are believed to 
	18 
increase with the severity of trauma and the number of years lived post injury (McKee et 
al., 2009). Similar neurodegenerative mechanisms catalyzed by mTBI likely explain the 
progressive neuronal loss, degeneration of brain tissue, and ventricular enlargement in the 
human brain.  
Another hallmark pathological consequence of acute mTBI is the formation and 
deposition of abnormal proteins, especially hyperphosphorylated tau (p-tau) and Aβ 
(McKee et al., 2013). In the normal and mature human CNS, tau stabilizes microtubules 
and does not accumulate or form NFTs. According to McKee et al. (2013), head trauma 
can cause tau to separate from axonal microtubules through mechanisms “that most likely 
include intracellular calcium influx, glutamate receptor-mediated excitotoxicity and 
kinase activation mediating hyperphosphorylation of intracellular tau.” After dissociating 
from axonal microtubules, the protein may undergo various alterations, including 
hyperphosphorylation, cleavage, or misfolding, which allow tau to abnormally aggregate 
and acquire toxicity (McKee et al., 2013). Tau pathology is known to commonly spread 
in diffuse extracellular, periventricular, and glial-glial patterns; however, recent studies 
have demonstrated that p-tau may cross the synaptic cleft through mechanisms involving 
prion-like misfolding or calcium dysregulation caused by oligomeric tau (McKee et al., 
2013; Kim et al., 2010; Clavaguera et al., 2009; Liu et al., 2012; De Calignon et al., 2012; 
Frost et al., 2009; Park et al., 2005).  
Although the development of neurodegenerative disease, such as CTE, takes place 
over many years, abnormal protein deposition may begin within hours of a single acute 
mTBI. In 1996, McKenzie et al. performed surgical brain tissue resection of individuals 
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who had suffered acute mTBI and found that tau-immnoreactivity was visible inside 
dystrophic axons, cell bodies, dendrites, and glial cells within 2 to 3 hours of the 
concussive event (McKenzie et al., 1996). Others have also reported that amyloid 
precursor production, Aβ production, and Aβ deposition increase by 30-38% within 2 
hours of a single mTBI (Murakami et al., 1998; Roberts et al., 1994; Ikonomovic et al., 
2004; McKee et al., 2009). It is believed that this Aβ deposition is frequently widespread 
throughout the neocortex rather than localized to injured areas (Graham et al., 1996). 
Furthermore, Aβ found within the cerebral cortex is predominately the Aβ42 type; 
whereas, Aβ found in the CSF is mostly Aβ40 (Gentleman et al., 1997). This pattern of 
distribution of Aβ within the brain is highly similar to that of AD (AD – is Aβ42 but, 
different cortical distribution), and this finding suggests that a single mTBI could be 
linked to disease development.    
The final hallmark pathological consequence associated with mTBI is the 
breakdown of the blood brain barrier (McKee et al.,2009, 2013). Tau pathology linked to 
mTBI is commonly periventricular and perivascular in location. Since, p-tau is believed 
to be cleared from the brain through paravenous drainage pathways, a likely explanation 
for the periventricular localization of p-tau deposition is the breakdown of the blood brain 
barrier due to mTBI (McKee et al., 2013). Likewise, a similar explanation for the 
common perivascular localization of tau pathology was given by Buee et al. in 1994 upon 
the discovery of decreased microvascular density within the brains of several former 
boxers with suspected CTE (Buee et al., 1994; McKee et al., 2009). These findings led 
the authors to argue that shearing forces caused by multiple mTBIs can lead to vascular 
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damage, allowing perivascular tauopathy to develop (Buee et al., 1994; McKee et al., 
2009).   
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NEUROPATHOLOGY 
Gross Pathology 
A wide array of both gross and microscopic pathological features are known to be 
characteristic of CTE. Grossly, affected individuals show varying degrees of atrophy of 
the cerebral cortex, commonly the frontal and medial temporal lobe, as well as the 
diencephalon and mammillary bodies (McKee et al., 2013). The ventricles are typically 
enlarged and a cavum septum pellucidum may be present along with fenestrations 
(McKee et al., 2013). Cerebellar focal scarring may also be visible as well as the loss of 
cells within the Purkinje layer of the cerebellum, degeneration of the locus coeruleus and 
pallor of the substantia nigra (Gardner, 2013). 
Microscopic Pathology 
Microscopically, CTE is a tauopathy characterized by pathological features that 
are distinct from those of other tau-related diseases, such as AD and FTLD (McKee et al., 
2009, 1013; Omalu et al., 2005, 2006). The hallmark pathological signs of CTE are the 
presence of sparse, moderate, or widespread deposition of both p-tau-immunoreactive 
NFTs and neuropil neurites (NNs) throughout various regions of the brain (Figure 1B) 
(McKee et al., 2009, 2013; Omalu et al., 2005, 2006). These NFTs may be flame-shaped, 
band-shaped, or present in small globular or large globular forms (Omalu et al., 2005, 
2011). Neuropil neurites are typically present as neuritic threads in both CTE and AD; 
however, dot-like and spindle-shaped NNs are uniquely characteristic of CTE (McKee et 
al., 2009). Classification of “sparse,” “moderate,” and “frequent” are determined using 
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the Consortium to Establish a Registry for AD (CERAD) neuritic plaque density scoring 
system (Omalu et al., 2011). Unlike other tauopathies, NFTs characteristic to CTE are 
typically perivascular and/or periventricular in location, and found predominately in the 
depths of the sulci of the neocortex (Omalu et al., 2005; McKee et al., 2009, 2013). Tau 
pathology may also be found in the superficial layers of the cerebral cortex, subcortical 
nuclei, basal ganglia, brainstem, and areas of the cranial nerve nuclei, specifically the 
dorsal raphe nucleus, locus coeruleus, basal nucleus of Meynert, and substantia nigra 
(Omalu et al., 2005, 2011). 
Similar to AD, Aβ plaque deposition is comonly found in cases of CTE (Figure 
1A) (McKee et al., 2013; Omalu et al., 2005; G. W. Roberts et al., 1994). As previously 
mentioned, the presence of Aβ plaques in CTE effected brains was first discovered by 
Roberts et al. in 1990. In this study, researchers reinvestigated the cases initially 
examined by Corsellis et al. in 1973 using immunocytochemical assays with antibodies 
raised against Aβ. Their studies revealed such extensive Aβ plaques in each of the cases 
with NFTs that they believed the “degree of β-protein deposition was comparable to that 
seen in AD” (Roberts et al., 1990). The work of Roberts et al. (1990) provided great 
insight into the relationship between the two diseases; however, later studies by Omalu et 
al. and McKee et al. discovered that the presence of Aβ deposition is much more 
inconsistent in CTE than AD (Figure 1D) (Omalu et al., 2005, 2006; McKee et al., 2009, 
2013). The complex relationship between CTE and AD will be discussed in greater detail 
in later sections of this paper.  
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Figure 1. NFTs, NN, and Aβ plaques associated with CTE. A, frequent diffuse Aβ 
plaques within the neocortex revealed by Aβ-specific immunostain. B, sparse NFTs and 
frequent NNs within the neocortex identified using tau-specific immunostain. C, NFT 
within a single neuron of the neocortex and a tau-positive dendritic process revealed by 
tau-specific immunostain. D,  Aβ-specific immunostain of hippocampus displays no 
signs of Aβ deposition. Figure taken from Omalu et al., 2005. 
 
In addition to NFTs and Aβ plaques, cases of CTE commonly display diffuse 
axonal injury and TAR DNA-binding protein 43 (TDP-43) abnormalities (McKee et al., 
2009, 2013; Omalu et al., 2005, 2006). Axonal injury may present as multifocal and 
perivascular varicosities in the cerebral cortex and subcortical white matter or as 
widespread, severe axonal loss throughout both of these regions (McKee et al., 2013). It 
is believed that axonal loss accounts for the headaches, attention deficits and short term 
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memory loss that appear during the early stages of CTE development when p-tau 
pathology is nascent (McKee et al., 2013). TDP-43 pathology is also commonly present 
during the early stages of CTE in the form of neurites, sparsely deposited within the 
cortex, medial temporal lobe and brainstem. In later stages, TDP-43 NFTs as well as 
intraneuronal and intraglial inclusions form throughout the cerebral cortex, subcortical 
white matter, diencephalon, and brainstem (McKee et al., 2013).  
Genetics 
Although all cases of of CTE are associated with mTBI, not all concussions lead 
to the development of CTE. This observation has led researchers to believe that genetics 
contribute to disease development, specifically allelic variation of the APOE gene (Mez 
et al., 2013). There are currently three known allelic variants of the APOE gene: 
APOE*4, APOE*3, and APOE*2. These variants express only minute differences in 
protein structure; however, they confer considerably different degrees of risk of 
developing neurodegenerative diseases (Omalu et al., 2005). APOE*4 poses the greatest 
risk, followed by APOE*3, and APOE*2 (Omalu et al., 2005). In normal individuals, 
apoE is a 34-kDA glycoprotein synthesized in the liver, and plays an important role in 
lipid and cholesterol metabolism (Omalu et al., 2011). Recent studies have shown that 
axonal injury triggers the expression of apoE in neurons (Mez et al., 2013). The neuronal 
form of apoE assumes a unique conformation that makes the protein particularly 
susceptible to proteolytic cleavage (Mez et al., 2013). Subsequent cleavage of neuronal 
apoE and accumulation of fragments confers the protein’s neurotoxic effects (Mahley & 
Huang, 2012; Mez et al., 2013). 
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The theory of a genetic risk factor for CTE was first proposed by Mayeux et al. in 
1995 in a study that demonstrated that individuals with APOE*4 are at greater risk of 
developing AD after suffering head trauma than individuals without this allele. Following 
this discovery, additional studies have shown that there is a higher incidence of “global 
scale” motor and psychological impairments amongst boxers with the APOE*4 allele 
compared to non-carriers (Jordan BD et al., 1997; Mez et al., 2013). Likewise, a study 
published by Kutner et al. in 2000 revealed that football players carrying APOE*4 were 
also at a higher risk of developing “global” neurological deficits, specifically in 
“cognition, processing speed, and attention” (Kutner et al., 2000; Mez et al., 2013). 
Finally, in 2009, Crawford et al. demonstrated that mice carrying transgenic human 
APOE*4 displayed unique microarray expression patterns in the cerebral cortex and 
hippocampus compared to those of mice without the APOE*4 gene (Crawford et al., 
2009; Mez et al., 2013). Although there is strong evidence that APOE*4 plays a role in 
the development of CTE, many details on its specific role in this process remain 
unknown (Mez et al., 2013). Future genome wide association studies (GWAS) and case-
specific personalized genomics may provide greater insight into the genetic contribution 
to disease development (Mez et al., 2013). 
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A CLOSER LOOK AT LANDMARK STUDIES 
Today, much of our knowledge of the prevalence of CTE beyond boxing has been 
discovered through the work of two research groups, Omalu et al. (2005, 2006, 2011) and 
McKee et al. (2009 and 2013). Collectively, the work of Omalu et al. and McKee et al. 
has shown that the disease once thought to occur only in boxers is a widespread 
neurodegenerative syndrome with suspected cases in former football players, boxers, 
hockey players, soccer players, military veterans, and other non-athletes with histories of 
TBIs. The following is a closer look at the contributions of each of these studies to our 
knowledge of the causes, clinical symptoms, and neuropathology of CTE as well as its 
relationship to other neurodegenerative diseases. 
Omalu et al. (2005, 2006) 
 As previously described, the 2005 study by Omalu et al. presented the first 
confirmed case of CTE in a former NFL player. The subject, Mike Webster, had played 
245 games as an offensive lineman in the NFL over 17 years, including a 177 consecutive 
game stretch. He had a medical history of cognitive impairments, mood instability, and 
Parkinsonian tremor (Omalu et al., 2005). Additionally, Webster was diagnosed with 
several co-morbid conditions, such as atrial fibrillation and coronary atherosclerotic 
disease, which ultimately led to his death by myocardial infarction (Omalu et al., 2005). 
Mike Webster did not sustain head trauma outside of football and did not have a family 
history of neurodegenerative disease (Omalu et al., 2005). 
 Twelve years following Webster’s retirement from football, Omalu et al. 
performed a postmortem examination of his brain that revealed little signs of gross 
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pathology (Omalu et al., 2005). There was no evidence of cortical contusions, infarcts, 
hemorrhages, or cerebral atrophy (Omalu et al., 2005). The subcortical white matter was 
not atrophic and the ventricles were of normal size (Omalu et al., 2005). Coronal sections 
of the cortex and corpus callosum lacked significant gross pathology as well (Omalu et 
al., 2005). The only significant pathological feature of the brainstem was mild pallor of 
the substantia nigra; however, the locus coeruleus appeared normal (Omalu et al., 2005). 
Microscopically, pathological findings were uniquely distinct from those of AD. 
While patients with AD typically show NFTs and amyloid plaques in the entorhinal 
cortex or hippocampus, these pathological features were predominately present in the 
cerebral cortex (Omalu et al., 2005). Specifically, immunohistochemical stains revealed 
diffuse extracellular amyloid plaques, sparse NTs, and both band and flame shaped NFTs 
throughout the frontal, temporal, parietal, occipital, and cingulate cortices (Omalu et al., 
2005). No NFTs or Aβ plaques were visible in the subcortical white matter or brainstem. 
Likewise, there was no evidence of Lewy bodies or amyloid angiopathy in the subject’s 
brain tissue (Omalu et al., 2005). Finally, Webster’s APOE genotype was determined to 
be E3/E3, which likely conferred some degree of disposition for disease development 
(Omalu et al., 2005). 
Although the 2005 study by Omalu et al. could not definitively determine a causal 
link between repetitive mTBI and CTE pathology, its significance to the scientific 
community was twofold. This sentinel case both exposed the potentially great prevalence 
of this largely unrecognized disease amongst former NFL players, and revealed the lack 
	28 
of empirical data available on the long-term neurodegenerative risks associated with 
professional football.  
In 2006, Omalu et al. conducted another study on a deceased former NFL player; 
however, postmortem pathological findings differed from those of the 2005 case. Similar 
to Mike Webster, this second subject played a long NFL career, experienced repetitive 
mTBIs, displayed signs of depression following retirement, and presented with moderate 
coronary artery disease (Omalu et al., 2006). Unlike Webster, this individual died of 
suicide by ingestion of ethylene glycol (Omalu et al., 2006). Autopsy did not reveal 
atrophy of the brain or septal defects, but pallor of the substantia nigra was present, 
similar to the findings of the 2005 study (Omalu et al., 2006). While sparse to frequent 
NFTs and NT were visible throughout the neocortex, Aβ plaques and Lewy bodies were 
absent. Researchers determined the individual’s APOE genotype to be E3/E4 (Omalu et 
al., 2006).  
Overall, the members of Omalu et al. were unable to determine why the 
pathological findings differed between the individuals examined in their 2005 and 2006 
studies. This ambiguity underscored the overall void of knowledge of the connection 
between football and CTE at the time. Due to the the inability to diagnose CTE in living 
humans, researchers were limited to studying the disease retrospectively through 
autopsies or indirectly through interviews of family members of the deceased. These 
constraints reduced the number of studies possible, making the findings of Omalu et al. 
(2005 and 2006) even more valuable. Between 2006 and 2011, Omalu et al. published 
several other works, including a case series of suspected CTE in 8 football players, 5 
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wrestlers, 1 boxer and 1 Iraqi war veteran (Omalu et al., 2006, 2010, 2011). This research 
group also devised a classification system for the 4 predominate CTE phenotypes and 
inspired additional studies by other groups, most notably McKee et al. (2009 and 2013). 
McKee et al. (2009, 2013) 
As mentioned above, the 2009 report by McKee et al. was the largest published 
case series on CTE at the time. This investigation both reviewed the 48 previously 
verified cases of CTE and contributed the autopsy results of 3 additional cases, including 
one football player and two boxers (Cases A, B, and C) (McKee et al., 2009). Of the total 
51 cases documented, 46 individuals were professional athletes, including 39 boxers, 5 
football players, 1 wrestler and 1 soccer player. Within 4 years of retirement, half of these 
athletes showed clinical signs of CTE including, violent behavior, memory impairments, 
slurred speech, impaired gait, and cognitive dysfunction. (McKee et al., 2009). Unlike 
previous studies, McKee et al. (2009) noted that two of the cases, one football player and 
one boxer, developed bipolar disorder alongside CTE after retirement (McKee et al., 
2009).  
Of the 3 new cases of CTE presented by McKee et al. (2009), the gross 
pathologies of only the two former boxers, Case B and Case C, are described. The brain 
of Case B, an 80-year-old African American man, was of normal weight and displayed 
mild atrophy in the frontal, parietal and temporal lobes of the cerebral cortex as well as 
the diencephalon, and mammillary bodies (McKee et al., 2009). Severe atrophy was 
visible in the anterior hippocampus, amygdala and entorhinal cortex. The third and lateral 
ventricles were enlarged, cavum septum pellucidum was present, and both the substantia 
	30 
nigra and locus coeruleus showed marked pallor present (McKee et al., 2009). Case C, a 
73-year-old Caucasian male, show largely similar gross pathology. Interestingly, these 
findings differ from those of Omalu et al. (2005 and 2006), which report little visible 
gross pathology in the football players examined. These differences in gross pathology 
may reinforce suggestion that football players and boxers experience different variations 
of CTE. 
Microscopically, Cases A, B, and C displayed prominent and frequent NFTs in 
the three superficial layers of the cerebral cortex (McKee et al., 2009). Similar to the 
findings of Omalu et al. (2005 and 2006), NFTs were especially prominent in the sulcal 
depths of the frontal and medial temporal lobe, commonly with perivascular localization 
(McKee et al., 2009). Tau-positive fibrillar astrocytes, known as “astrocytic tangles,” 
were multifocal, and most noticeable in subpial regions and near vessels (McKee et al., 
2009). Astrocytic tangles and NNs in the dot-like, spindle-shaped, and threadlike forms 
were also found in the frontal and temporal cortices as well as the white matter of the 
corpus callosum (McKee et al., 2009). The hippocampus, entorhinal and transentorhinal 
cortices, amygdala, medulla, thalamus, and olfactory bulb showed dense tau pathology, 
consisting of NFTs, NNs, and astrocytic tangles. The substantia nigra revealed marked 
neuronal loss and pallor (McKee et al., 2009). 
Also similar to the findings of Omalu et al. (2006), Aβ plaque deposition varied 
amongst the 51 cases. Of the three new cases, only Case B displayed Aβ plaques located 
in the frontal, parietal, and temporal cortices as well as no vascular amyloidopathy 
(McKee et al., 2009). Of the 51 total cases, 24 showed diffuse Aβ plaques, 13 revealed 
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neuritic plaques, and 3 displayed amyloid angiopathy (McKee et al., 2009). This variation 
in the frequency, location, and distribution of Aβ plaque deposition represents a 
similarity in CTE pathology found in football players and boxers, but also a marked 
difference from the pathology of AD, which displays more consistent patterns of Aβ 
plaque deposition. Despite these findings, McKee et al. (2009) verified previous claims 
made by Roberts et al. (1990) that the NFTs and Aβ plaques found in both CTE and AD 
are “immunocytochemically identical,” which serves as a significant similarity between 
the pathologies of both diseases. Overall, the results of McKee et al. (2009) underscored 
the ambiguity surrounding the relationship between both diseases.  
As previously mentioned, one of the most profound findings of this study was the 
difference in the duration of symptomatic illness between football players and boxers, i.e. 
the number of years between the onset of symptoms and death of the effected individual. 
Because this statistic was considerably longer in cases involving boxers than football 
players, McKee et al. (2009) revealed that the symptoms of football players progress 
more quickly and result in earlier deaths compared to the boxers. This discovery was 
important as it provided evidence that would later support the two subtype hypothesis 
presented by Stern et al. in 2013. The authors of this 2013 study argued that most cases of 
CTE display one of two common clinical presentations: the first is characterized by 
mostly mood and behavioral abnormalities with an earlier age of onset and the second is 
made up of mostly cognitive deficits with a later age of onset. Together, the findings of 
McKee et al. (2009) and Stern et al. (2013) suggest that football players and boxers may 
experience two different clinical subtypes of CTE. In football players, behavioral and 
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mood changes appear earlier, progress more quickly, and lead to earlier and often 
extreme deaths. In boxers, the onset of cognitive symptoms occurs later and progresses 
more slowly leading to death at older ages compared to football players. Gardner (2013) 
argued further that the proposed cognitive subtype is frequently accompanied by motor 
impairments that appear much earlier than cognitive symptoms, and in some cases may 
be more severe. Overall, the findings of Omalu et al., (2005, 2006), McKee et al. (2009), 
Stern et al., (2013), and Gardner et al., (2013) provide data that can be used as evidence 
to argue that football players and boxers suffer from different variations of the same 
disease.  
In 2013, McKee et al. expanded on their 2009 study and published what is 
currently the largest CTE-related case series to date. In this report, the authors review the 
clinical and pathological findings of 85 individuals with histories of repetitive mTBIs, 
including 80 former professional athletes of contact sports, 3 military veterans with no 
history of participation in contact sports, one subject who suffered multiple mTBIs from 
falling, and one individual who displayed a repetitive head-banging behavior (McKee et 
al., 2013). The experimental group consisted of 84 males and 1 female with an overall 
mean age of 54.1 ± 23.3 years (McKee et al., 2013). Researchers compared this 
experimental cohort to the brains of 18 individuals with normal cognitive ability and no 
prior history of repetitive brain trauma; 7 were military veterans and 3 were athletes of 
non-contact sports (McKee et al., 2013). The control group consisted of 17 males and 1 
female with an overall mean age of 62.0 ± 17.4 years (McKee et al., 2013).  Researchers 
found that 7 of the 18 control brains were negative for NFTs, and 11 control brains 
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displayed AD-type NFTs within the hippocampus and entorhinal cortex (McKee et al., 
2013). Three control brains showed diffuse Aβ deposition in vascular and plaque forms. 
None of the control subjects displayed NFTs within the sulcal depths or superficial 
laminae of the cerebral cortex (McKee et al., 2013). 
In the experimental group, 17 out of 85 of the examined brains surprisingly 
displayed no signs of gross or microscopic CTE pathology. Sixty-eight individuals 
revealed p-tau NFTs and astrocytic tangles characteristic of CTE; 50 of these subjects 
were former football players including 33 former NFL players, 1 former CFL player, 9 
college football players, and 6 high school football players, along with 5 former hockey 
players, 7 professional boxers, 1 amateur boxer, and 1 professional wrestler (McKee et 
al., 2013). Three military veterans as well as the single individual who engaged in 
repetitive head banging also showed micropathological signs of CTE (McKee et al., 
2013). 
In addition to the typical tau pathology, Aβ deposition was found in the brains of 
30 of the 85 individuals studied (McKee et al., 2013). Deposits were present as diffuse 
plaques, neuritic plaques or vascular amyloid. These findings reinforced previous 
hypotheses that Aβ deposition is characteristically inconsistent in cases of CTE (Omalu 
et al., 2005; McKee et al., 2009, 2013). Unlike previous studies, McKee et al. (2013) 
found that subjects with Aβ plaques were markedly older than those in which Aβ plaques 
were absent. Finally, Lewy body inclusions of α-synuclein protein were identified in 15 
of the individuals in the experimental group, specifically located in the olfactory bulb, 
medulla, and amygdala (McKee et al., 2013).  
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Although the studies of Omalu et al. (2005 and 2006) provided unprecedented 
insight into cases of CTE in former NFL players, the work of McKee et al. (2009 and 
2013) truly expanded our knowledge of the disease in contexts beyond boxing. Because 
both case series presented by McKee et al. were of such a large scale, their results had a 
considerable influence on our understanding of CTE. Their discoveries that were similar 
to those of Omalu et al., such as those of the clinical symptoms and pathological findings 
of the disease, greatly strengthened the validity of our prior knowledge. Conversely, the 
results of McKee et al. that differed from those of previous studies not only contributed 
new knowledge, but also conferred greater credibility to these new hypotheses because of 
the large sizes of their case series. Two of these new discoveries included the 
inconsistency of Aβ deposition, which is characteristic of CTE, and the differences in the 
length of symptomatic illness between football players and boxers. Certainly, our 
understanding of CTE remains in its infancy; however, the work of Omalu et al. and 
McKee et al. has profoundly advanced what is known of the disease. To guide further 
research, both research groups have constructed classification systems for CTE that will 
be discussed in the following section.  
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CLASSIFICATION SYSTEMS 
Both classification systems devised by Omalu et al. and McKee et al., rely on 
postmortem pathological findings in diagnosing CTE. The scheme developed by McKee 
et al. consists of four stages; whereas, the system formulated by Omalu et al. classifies 
four distinct phenotypes (Table 2). Currently, no single, universal system of classification 
has been established and both systems are utilized in CTE research. 
Four Stages  
According to McKee et al. (2013), Stage I is characterized by focal, perivascular 
deposits of p-tau within the sulcal depths of the superior, inferior, or lateral frontal cortex 
(McKee et al., 2013). Individuals with stage I CTE may present clinically with frequent 
headaches and trouble with concentration or attention (McKee et al., 2013). In stage II 
CTE, McKee et al. describes the presence of focal NFTs in the superficial layers of the 
cortex, the locus coeruleus and nucleus basalis of Meynert (McKee et al., 2013). Clinical 
signs of stage II CTE include impulsivity, mood instability, depression, and short-term 
memory loss (McKee et al., 2013). McKee et al. classify stage III CTE grossly as mild 
cerebral atrophy, marked dilation of the ventricles, septal defects, concave third 
ventricles, and loss of pigmentation in the locus coeruleus and susbstantia nigra 
consistent with neuronal damage (McKee et al., 2013). Microscopically, stage III CTE 
shows dense focal p-tau deposits in the medial temporal lobe, specifically the 
hippocampus, amygdala, and entorhinal cortex, as well as widespread NFTs throughout 
the spinal cord and brain, specifically in the frontal, temporal, parietal, insular, and septal 
cortices, diencephalon, and brainstem (McKee et al., 2013). Individuals with stage III 
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CTE show significant cognitive deficits, impaired executive function, marked memory 
loss, explosivity, disorientation, and depression (McKee et al., 2013). Finally, McKee et 
al. (2013) states that individuals with stage IV CTE display significant loss of brain 
weight as well as degeneration of the cerebral cortex and diencephalon, distinct pallor of 
the susbstantia nigra and locus coeruleus, ventricular dilation and septal defects (McKee 
et al., 2013). Microscopic pathology of stage IV CTE consists widespread NFTs 
throughout the CNS grey and white matter, significant gliosis and neuronal loss within 
the cortex and sclerosis of the hippocampus (McKee et al., 2013).  Clinically, stage IV 
CTE is characterized by profound executive function deficiencies, loss of short-term 
memory, aggression, paranoia, suicidality, and problems with spatial orientation. (McKee 
et al., 2013). 
Of the 35 former (34 NFL and 1 CFL) football players examined by McKee et al. 
(2013), 1 subject showed no signs of disease, 3 individuals showed pathology consistent 
with stage I CTE, three subjects displayed stage II CTE, 9 presented stage III CTE, 7 
displayed stage IV CTE, and the remaining individuals were considered to have various 
stages of CTE alongside other neurodegenerative diseases, including AD, Lewy body 
disease, FTLD, and MND (McKee et al., 2013). Of the 34 former NFL players studied, 
31 subjects (89%) showed either pure stage III CTE, pure stage IV CTE or stage III/IV 
along with other co-morbid neurodegenerative disease (McKee et al., 2013). Ninety-four 
percent of the former professional football players examined showed clinical symptoms 
of CTE with symptom onset at a mean age of 54.1 ± 14.1 years (McKee et al., 2013). Of 
these individuals 26% were former offensive linemen, 20% were running backs, 14% 
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were defensive linemen, 14% were linebackers, 6% were quarterbacks, 6% were 
defensive backs, 6% were tight ends and 6% were wide receivers (McKee et al., 2013). 
Researchers found that one of the five former professional hockey players showed no 
signs of CTE, three showed clinical and pathological symptoms consistent with stage II 
CTE, and one individual displayed stage III with the presence of Lewy bodies (McKee et 
al., 2013).   
Four Phenotypes 
The method of classification devised by Omalu et al. in 2011 consists of 4 distinct 
CTE phenotypes determined by the microscopic pathology present in effected 
individuals. These phenotypes serve as general guidelines for classification and the 
criteria listed below is not absolute for each phenotype (Omalu et al., 2011). The first 
phenotype is characterized by the presence of sparse to frequent NFTs and NTs within 
the cerebral cortex and brainstem, no NFTs or NTs present in the cerebellum and no 
diffuse Aβ plaques present in the cerebral cortex (Omalu et al., 2011). NFTs and NTs 
may or may not be present in the subcortical regions. The second phenotype also shows a 
combination of sparse to frequent NFTs and NTs throughout the cortex and brainstem, 
absence of NFTs and NTs in the cerebellum, and a combination of sparse to frequent 
diffuse Aβ plaques throughout the cerebral cortex (Omalu et al., 2011). Like the first 
phenotype, NFTs and NTs may or may not be present within subcortical nuclei and basal 
ganglia. The third phenotype reveals moderate to frequent NFTs and NTs in the 
brainstem, little to no NFTs and NTs in the cortex and subcortical regions, no NFTs and 
NTs in the cerebellum or Aβ plaques in the cortex (Omalu et al., 2011). Finally, the 
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fourth phenotype consists of little to no NFTs and NTs in the cortex, brainstem and 
subcortical regions, absence of NFTs in the cerebellum, and absence of Aβ plaques 
(Omalu et al., 2011). According to Omalu et al. (2011), the exact cause of the phenotypic 
spectrum of CTE is currently unknown. As previously mentioned, the two systems 
discussed above represent methods for classifying and diagnosing CTE postmortem. 
Although there is currently no reliable method for providing an in vivo diagnosis, Jordan 
et al. recently proposed a system for diagnosing CTE clinically that will be discussed in 
the following section (Jordan et al., 2013).      
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Table 2. Neuropathology of CTE Classification Systems. McKee et al. (2013) 
proposed a system of 4 stages of CTE. Omalu et al. (2011) identified 4 phenotypes of 
CTE. Table taken from Gardner et al., 2013. 
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A PROPOSED SYSTEM FOR CLINICAL DIAGNOSIS 
As described above, a definitive diagnosis of CTE may only be made postmortem 
following a thorough examination of neuropathology (Jordan et al., 2013). Clinical 
diagnoses of CTE have been considered unfeasible primarily for two reasons. First, many 
of the neurodegenerative symptoms of CTE appear long after an individual suffered 
multiple mTBIs, and second, CTE shares many of the same clinical symptoms of other 
neurodegenerative diseases that commonly appear in old age (Jordan et al., 2013). Due to 
the inability to diagnose CTE in vivo, past and current research has been limited to 
retrospective analyses, and the lack of prospective studies significantly hinders both the 
quality and quantity of what is known of the disease. Recently, Jordan et al. (2013) has 
proposed a system for providing a clinical diagnosis of CTE that consists of four 
categories: definite, probable, possible, and improbable disease.  
The diagnosis of “definite” CTE is given when a patient presents with numerous 
clinical symptoms associated with CTE, such as various motor, behavioral, and cognitive 
deficits, as well as pathological confirmation of NFTs (Jordan et al., 2013). It is not 
required that Aβ plaques or TDP-43 be present. Jordan et al. (2013) suggests clinicians 
use the classification schemes presented by Omalu et al. (2011) and McKee et al. (2013) 
to aid in diagnosing “definite” CTE.  
To diagnose an individual with “probable CTE,” a patient must present with 
distinct clinical signs of two or more of the following conditions: behavioral deficits, 
cognitive deficits, pyramidal tract disease and/or extrapyramidal disease, and cerebellar 
dysfunction (Jordan et al., 2013). Neuroimaging, specifically 2-(1-{6-[(2-[fluorine-
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18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile (FDDNP) positron 
emission tomography (PET), is particularly valuable in diagnosing “probable CTE.” In 
2013, Small et al. demonstrated that FDDNP-PET may be used to effectively measure tau 
and Aβ deposition in the brain, and revealed that five retired professional football players 
displayed increased subcortical and cortical deposits (Jordan et al., 2013; Small et al., 
2013). Negative tau PET scans may rule out “probable CTE,” and negative Aβ PET scans 
may rule out both preclinical and overt AD (Jordan et al., 2013). Additional imaging 
results that suggest a “probable CTE” diagnosis are signs of glucose hypometabolism 
visible in PET scans, evidence of tissue damage found through diffusion tensor imaging 
(DTI), and hypoperfusion seen in single-photon emission CT (SPECT) (Jordan et al., 
2013). Jordan et al. (2013) suggests that “possible CTE” consists of clinical findings that 
show overlap between various neurodegenerative diseases, but CTE cannot be ruled out. 
Finally, “improbable CTE” diagnoses should be made when patients exhibit symptoms 
consistent with non-mTBI-related neuropathy, such as neoplasia, and signs characteristic 
of CTE are absent (Jordan et al., 2013). Overall, these four categories of clinical 
diagnoses of CTE serve as general guidelines and are not definitive requirements. Further 
research into the biomarkers of CTE and consensus clinical and pathological criteria for 
the disease are necessary before a reliable, universal method of diagnosing CTE in vivo 
may be established.    
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CONNECTIONS TO OTHER NEURODEGENERATIVE DISEASES 
Clinical Symptoms 	 As previously mentioned, one of the difficulties associated with providing a 
clinical diagnosis of CTE is its symptomatic overlap with several other 
neurodegenerative diseases including, AD, Parkinson’s Disease (PD), frontotemporal 
lobar degeneration (FTLD), motor neuron disease (MND) and Lewy body disease (LBD) 
(Tartaglia et al., 2014). The characteristically late onset of CTE symptoms makes 
definitive diagnoses of the pure disease less common. This section will provide a 
discussion of the clinical and pathological connections between CTE and the most 
common comorbid neurodegenerative conditions, specifically FTLD, MND, PD and AD.  
FTLD is the most prevalent neurodegenerative disease in individuals less than 65 
years of age, and shares many of the same clinical symptoms as CTE (Tartaglia et al., 
2014). Specifically, FTLD presents with five phenotypes caused by differences in focal 
pathology (Tartaglia et al., 2014). These phenotypes include, behavioral variant 
frontotemporal dementia (bvFTD), primary progressive aphasia, frontotemporal 
degeneration in combination with motor neuron disease (FTD-MND), progressive 
supranuclear palsy (PSP), and corticobasal syndrome (CBS) (Tartaglia et al., 2014). 
bvFTD displays the greatest overlap with CTE, and has been associated with mTBI 
(Tartaglia et al., 2014). Overlapping clinical symptoms include personality disorders, 
apathy, and social instability (Tartaglia et al., 2014). As indicated by its name, bvFTD 
displays similar gross pathology to CTE presenting as atrophy of the cortex as well as 
similar microscopic pathology, including TDP-43 abnormalities (Tartaglia et al., 2014). 
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Unlike individuals with CTE, patients with bvFTD rarely display significant memory 
impairment (Mez et al., 2013). 
MND comorbid with CTE is known as a condition named  “chronic traumatic 
encephalomyelopathy” (Mez et al., 2013). Symptoms of MND typically appear before 
those of CTE and include muscle spasms, fasciculations, weakness, and muscle atrophy, 
most frequently in muscles of the upper limb and neck (Mez et al., 2013). Cognitive and 
behavioral impairments characteristic of CTE, including depression, loss of short term 
memory, disinhibition, paranoia and cognitive deficiencies, commonly appear several 
years after developing symptoms of MND (McKee et al., 2013). According to McKee et 
al. (2013), patients with CTE-MND tend to die from respiratory insufficiency at younger 
ages than individuals with pure CTE. 
 The overlap of clinical symptoms between PD, AD, and CTE is profound. CTE 
patients commonly present with Parkinsonism, impaired gait, and cognitive deficits, 
which are all visible in PD (Tartaglia et al., 2014). Additionally, the hallmark sign of AD, 
short-term memory loss and dementia, is frequently observed in patients with suspected 
CTE. Other overlapping symptoms, including learning impairment, depression, and 
behavioral abnormalities have also known to appear in cases of AD (Mez et al., 2013). 
 Like CTE, numerous studies have linked the development of AD with repetitive 
head injuries (Tartaglia et al., 2014). In 2000, Plassman et al. published the results of an 
investigation of the medical records of Navy and Marine World War II veterans that 
revealed a much higher incidence of AD amongst veterans who had experienced brain 
trauma compared to those who had not (Plassman et al., 2000; Montenigro et al. 2015). 
	44 
Plassman et al. also found that the risk of developing AD increased with the severity of 
mTBIs, and that even mild head trauma showed a correlation with the development of 
dementia (Plassman et al., 2000; Montenigro et al. 2015). In 2003, Fleminger et al. 
published a case series involving 15 individuals that ultimately revealed a “significant 
link” between head injury and AD development (Montenigro et al., 2015). Together, 
these studies provided greater insight into the relationship between CTE and AD by 
demonstrating that both diseases are similarly connected to mTBI and may develop 
through analogous mechanisms. 
 Because of the significant overlap in the clinical presentations of CTE and AD 
and the inability to diagnose CTE in vivo, some researchers have argued that cases of 
CTE may have been historically misdiagnosed as AD (Montenigro et al., 2015). For 
example, Sayed et al. conducted a study in 2013 that compared the clinical symptoms of 
AD patients with histories of mTBIs to those of AD patients without histories of mTBIs 
(Sayed et al., 2013; Montenigro et al. 2015). Researchers found that a significant 
proportion of patients who had suffered head trauma displayed symptoms that were more 
consistent with those of CTE than those of AD, specifically anxiety, disinhibition, 
depression, and motor impairments (Sayed et al., 2013; Montenigro et al. 2015). 
Additionally, a greater proportion of subjects with histories of mTBIs showed decreased 
levels of amyloid angiopathy, despite normal levels of tauopathy, upon postmortem 
examination than those without histories of head injuries (Sayed et al., 2013; Montenigro 
et al. 2015). Although the prevalence of such misdiagnoses is unknown, examples of 
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these errors underscore the similarities between the clinical presentations of CTE and 
AD. 
Pathological Findings 	 CTE displays distinct pathology; however, it is a member of a family of other 
known tauopathies, including FTLD, PSP, CBS, and AD, that displays considerable 
pathological overlap. In 2013, McKee et al. reported that 37% of CTE cases examined 
indicated pathological signs of comorbid disease, including FTLD, PD, MND and AD. 
The authors of this study suggest that these comorbidities develop when axonal injury 
catalyzes molecular pathways that lead to the formation and aggregation of multiple 
abnormal protein types, such as p-tau, Aβ, TDP-43, and α-synuclein (McKee et al., 
2013). As previously described, past studies have demonstrated that repetitive brain 
trauma is a risk factor for both AD and PD, and their findings reinforce this hypothesis 
(McKee et al., 2013).  
An alternative explanation for the development of comorbid disease is the 
presence of cross-seeding between p-tau and other abnormal proteins characteristic of 
neurodegenerative conditions (McKee et al., 2013). Cross-seeding takes place when 
oligomeric seeds of one abnormal protein induce the exponential aggregation of a 
different type of mutated or misfolded protein (Morales et al., 2013). This mechanism 
likely accounts for the similar pathological findings in CTE and FTLD (McKee et al., 
2013). Like individuals with CTE, subjects with FTLD commonly display both NFTs and 
TDP-43 aggregates; however, in FTLD these findings are typically confined to the 
hindbrain and basal ganglia (McKee et al., 2013). According to McKee et al. 2013, 
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individuals with CTE-MND also commonly display severe TDP-43 aggregates that are 
believed to develop through cross-seeding. This pathology typically presents as 
widespread neuronal, glial, and neuritic inclusions found throughout the neocortex and 
spinal cord (McKee et al., 2013).  
The relationship between CTE and AD is ambiguous. Both diseases exhibit 
similar pathology; prior research has shown that NFTs and Aβ found in the two diseases 
are immunocytochemically identical (McKee et al., 2009). Because repetitive brain 
trauma is a known risk factor for AD, it has been suggested that both diseases may follow 
a common mechanism of pathogenesis (McKee et al., 2009).  
Recent studies have also revealed similarities in clinicopathological correlation 
between the two diseases (Mez et al., 2013). Researchers believe that the memory deficits 
common to both AD and CTE are caused by NFT accumulation specifically in the 
hippocampus, parahippocampal gyrus, and entorhinal cortex (Mez et al., 2013). 
Additionally, tau and Aβ pathology localized to the superior, dorsolateral, and lateral 
portions of the frontal cortex lead to the loss of executive function in patients with both 
diseases (Mez et al., 2013). NFTs and Aβ deposition in the orbitofrontal cortices or 
temporal cortices are believed to account for the disinhibition and impulsivity associated 
with CTE (Mez et al., 2013). Finally, deficits in motor function and parkinsonianism are 
thought to be caused by pathology found in the basal ganglia and substantia nigra (Mez et 
al., 2013). 
Similar to its role in CTE pathogenesis, APOE*4 is believed to contribute to the 
development of AD (Omalu et al., 2005). In 2005, Omalu et al. found that the presence of 
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one or two APOE*4 alleles increases the risk of developing sporadic AD and leads to an 
earlier onset of symptoms in late-onset AD (Omalu et al., 2005). Additionally, Farrer et 
al. (1997) demonstrated that the APOE*4 allele is a major risk factor for AD in all 
indiviudals between age 40 and age 90 regardless of race or gender (Montenigro et al., 
2015). Studies have also suggested that the APOE*4 allele not only serves as a risk factor 
for both AD and CTE, but is also associated with poor prognoses in affected individuals 
(Crawford et al., 2009; Montenigro et al., 2015). These findings strengthen previous 
suggestions that CTE and AD may develop through similar mechanisms. 
Although AD and CTE display many similar pathological findings, there are also 
clear differences between the pathologies of the two diseases. As previously mentioned, 
the most significant difference between CTE and AD pathology is the inconsistency of 
Aβ deposition in cases of CTE (McKee et al., 2013; Mez et al., 2013; B. I. Omalu et al., 
2005). Omalu et al. reported the presence of Aβ plaques in subject of their 2005 study; 
however, Aβ deposition was absent in the brain of the professional football player 
examined in 2006. Likewise, McKee et al. found β-amyloid in only 47% of CTE cases 
studied in 2009 and 44% of cases studied in 2013.  
Another significant difference between the pathologies of AD and CTE is the 
order in which specific regions of the brain become effected during disease development 
(Figure 2). For example, according to the CTE staging system proposed by McKee et al. 
in 2013, stage I tau pathology first appears perivascularly, localized in the depths of the 
sulci of the frontal cortices and locus coeruleus (McKee et al., 2013; Montenigro et al., 
2015). In stage II, pathological findings become apparent in the diencephalon and nucleus 
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basalis of Meynert, and in stage III this pathology spreads to the hippocampus amygdala 
and basal ganglia (McKee et al., 2013; Montenigro et al., 2015). Finally, in stage IV, the 
medulla, cerebella, and cervical spinal cord show signs of pathology (McKee et al., 2013; 
Montenigro et al., 2015). 
 
 
Figure 2: Progression of tau pathology in CTE and AD. In CTE tau pathology first 
appears in various regions of the neocortex and locus coeruleus before spreading to 
diencephalon, medial temporal lobe, brainstem and cerebellum. In AD, tau pathology 
originates in the brainstem before appearing in the entorhinal cortex, various regions of 
the temporal lobe, and finally the neocortex. Figure taken from Montenigro et al. (2015). 
Figure created based on information from Braak et al. (2011), McKee et al. (2013), and 
Stein et al. (2014). 
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According to the Braak staging system for AD, the disease develops in essentially 
the opposite regional pattern to that of CTE. In Stage I AD, tau pathology first appears in 
the locus coeruleus, upper raphe nuclei, and magnocellular nuclei (Braak, 2011; 
Montenigro et al., 2015). This pathology then spreads to the transentorhinal cortex and 
entorhinal cortex in stage II AD, and later becomes visible in the hippocampus, 
amygdala, basal temporal, insular, and basal frontal cortices in stage III of the disease 
(Braak, 2011; Montenigro et al., 2015). Unlike CTE, in which these pathological findings 
commonly appear in stage I, widespread neocortical tau pathology becomes apparent in 
the fourth and final stage of AD (Braak, 2011; Montenigro et al., 2015). Likewise, the 
cerebellum is typically spared from signs of tauopathy in AD but, it is commonly effected 
in cases of CTE (Braak, 2011; Montenigro et al., 2015). 
Although it is well known that the consistency of Aβ deposition is a major 
difference between the pathologies of CTE and AD, recent studies have also suggested 
that the distribution of Aβ deposition within the brain may differ between the two 
diseases. In 2013, Stein et al. reported that subjects with both CTE and AD displayed 
greater accumulations of Aβ within the sulcal depths than the gyral crests compared to 
patients with AD alone. The results of McKee et al. (2013) also support these findings 
(Figure 3). According to McKee et al. (2013), tau pathology characteristic of AD is more 
commonly located in the deeper cortical layers than the cerebral sulci. Similarly, AD tau 
pathology is rarely perivascular or periventricular, as it it is in CTE (McKee et al., 2013; 
Mez et al., 2013). These differences between the distributions of tau pathology in CTE 
and AD suggest that repetitive brain trauma may alter AD tau pathology (Meehan et al., 
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2015). Although many connections have been drawn between the clinical symptoms and 
pathological findings of CTE and AD, numerous questions regarding the relationship 
between the two diseases remain unanswered. 
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Figure 3: Differences in distribution of tau pathology in CTE and AD. In CTE, p-tau 
NFTs are commonly found in the (a) superficial cortical layers of the (b) cerebral sulci. 
NFTs are also commonly (c) perivascular in location, and visible in the (d) absence of Aβ 
plaques. In AD, tau pathology is usually confined to the (e) deeper cortical layers, and 
absent in (f) the cerebral sulci and (g) perivascular locations. Finally, NFTs are typically 
accompanied by Aβ plaques in AD. Figure taken from Montenigro et al., 2015. Figure 
created based on the findings of McKee et al., 2013.  
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PREVENTION 
The most effective method for preventing the development of CTE is to decrease 
participation in contact sports altogether; however, this strategy is impractical and 
unrealistic. An alternative and reasonable approach is to decrease the frequency of mTBIs 
experienced by athletes of contact sports (McKee et al. 2009). This may be accomplished 
by penalizing players for intending to inflict blows to the head during games as well as 
devising extensive guidelines to ensure athletes return to play safely (McKee et al. 2009). 
Currently, there is no reliable, empirical method of assessing the extent of neurological 
injury immediately following a concussion; thus, team doctors and trainers must be 
hyper-vigilant of players who display concussive symptoms (McKee et al. 2009). Simple 
strategies, such as observing play for possible concussive blows and preventing athletes 
from returning to play until they receive proper neurological testing, could reduce the 
prevalence of CTE amongst athletes significantly.  
Creating and implementing stringent concussion protocols are paramount in 
protecting player safety. Neurological testing may be used to assess the extent of 
neurological dysfunction in the days following injury as well as to estimate the correct 
amount of time that players should wait before returning to play (McKee et al. 2009). 
Specifically, PET, magnetic resonance imaging (MRI), transcranial magnetic stimulation, 
and other tests can provide insight into the severity of athletes’ injuries, and have 
demonstrated that the effects of mTBI may be visible for 2 to 4 weeks following a 
concussive event (McKee et al. 2009). Previous research has also shown that an athlete is 
at greater risk of experiencing a second concussion during the first week after the initial 
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injury (McKee et al. 2009). Thus, proper care during this time period is critical in 
protecting player safety and preventing repetitive concussions, which may lead to 
neurodegenerative disease (McKee et al. 2009). Furthermore, individuals require 4 to 6 
weeks on average to fully recover from a severe concussion (McKee et al. 2009). The 
substantial length of this recovery period makes the need for proper concussion 
management even more significant.  
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DISCUSSION AND CONCLUSIONS 
The recent surge of interest in the role of mTBI in the development of CTE has 
led to great advances in our understanding of the disease’s etiology. Currently, we know 
that CTE is a progressive and irreversible neurodegenerative syndrome that has been 
associated with unique patterns of clinical symptoms and neuropathology. Recent studies 
have connected multiple concussions with the development of specific motor, behavioral, 
mood, and cognitive changes over a period of many years. Individuals with suspected 
CTE commonly present with impairment in short term memory, impairments in executive 
function, impulsivity, aggression, depression, paranoia and numerous other behavioral 
and personality changes. There is also evidence that supports the hypothesis of two 
different clinical presentations of the disease (Stern et al., 2013). Although athletes may 
present with either sub-type, boxers more commonly present with cognitive and motor 
deficits; whereas, football players predominately display mood and behavioral 
abnormalities (McKee e al., 2009). Furthermore, postmortem examinations of individuals 
with confirmed CTE commonly display similar gross and microscopic pathological 
findings. These include atrophy of the frontal and medial temporal lobed, septal defects, 
pallor of the substantia nigra, and perivascular accumulations of hyperphosphorylated tau 
both within the depths of the sulci as well as the superficial layers of the neocortex 
(McKee et al. 2013). Aβ deposition has been associated with CTE; however, its presence 
is less consistent than in cases of AD (McKee et al. 2013). Finally, we know that the 
development of these clinical and pathological findings has been largely associated with 
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repetitive head trauma suffered in contact sports and there is some degree of increased 
prevalence of the disease amongst former athletes. 
Despite this progress, our understanding of the CTE is nascent, and many 
important aspects of the disease remain unknown. Although all confirmed cases of CTE 
have been linked to repetitive head injuries, not all individuals who have suffered 
multiple mTBIs develop CTE (McKee et al., 2013; Mez et al., 2013; Montenigro et al., 
2015). Conversely, there have been no confirmed cases of CTE in individuals who have 
not suffered multiple mTBIs. As stated by Montenigro et al., these findings suggest that 
head trauma is a necessary, but not sufficient factor in developing CTE (Montenigro et 
al., 2015). Other risk factors, such as genetics, likely play a role in disease development 
(Crawford et al., 2009; McKee et al., 2013; B. Omalu et al., 2011).  
 One of the major limitations on past and current CTE research is the inability to 
diagnose CTE in vivo. The effects of this constraint have been threefold. First, it has 
restricted CTE research to retrospective analyses, consisting of mostly case studies, case 
series, surveys and autopsies. Studying CTE retrospectively hinders our ability to 
accurately link clinical symptoms and pathological findings as well as to confidently 
determine that repetitive mTBIs cause disease development. Secondly, this method has 
allowed selection bias to influence our understanding of the prevalence of CTE within 
society. For example, symptomatic patients are more likely to be referred for autopsies 
than asymptomatic ones. Likewise, families of deceased individuals who showed signs of 
CTE may feel more compelled to donate the brain of their deceased family member to 
science (Meehan et al., 2015). Finally, the inability to provide an in vivo diagnosis both 
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creates the possibility of misdiagnosing CTE as other similar neurodegenerative diseases, 
such as AD, and allows possible cases of CTE to go unidentified (Gavett et al., 2010; 
Stern et al., 2011; Montenigro et al., 2015). The International Classification of Diseases 
does not recognize CTE as a formal diagnosis; thus, it is entirely possible that the 
prevalence of CTE is higher than currently believed (Montenigro et al., 2015). Due to the 
limited number of subjects available for study, each misdiagnosed case of CTE also 
represents a lost opportunity to expand our knowledge. While past and current 
retrospective studies have led to numerous hypotheses regarding the epidemiology of 
CTE, the lack of prospective evidence necessitates further research to reinforce our 
understanding of the disease. 
 Future CTE research must focus on developing reliable and accurate methods for 
diagnosing the disease in vivo. The first step towards achieving this goal is to establish 
clear, consensus clinical and pathological criteria for CTE diagnosis.  A deeper 
understanding of potential biomarkers of CTE pathology found in tissue, CSF and serum, 
will greatly enhance our ability to precisely and efficiently diagnose the disease in living 
humans. The ability to provide an in vivo diagnosis is critical as it will allow researchers 
to perform prospective studies on the disease and relinquish the limitations posed by the 
current retrospective approach. In the future, longitudinal and prospective studies on the 
development of CTE will ultimately allow researchers to accurately estimate its 
prevalence in modern society and confirm the causal link between repetitive head trauma 
and disease development. 
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